Key Takeaways AbbVie stock is up 22.5% in 2025, beating its industry, sector and the S&P 500 index.Strong sales of Skyrizi and Rinvoq are replacing Humira and driving top-line growth.Acquisitions in immunology, oncology and neuroscience strengthen AbbVie's pipeline.AbbVie (ABBV) has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Sourc ...

AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq and Skyrizi. The stock has surged by nearly 22% since th ...

Overall, Wall Street rates NEE stock as a “Moderate Buy.” Of the 21 analysts that cover the stock, 12 rate it a “Strong Buy,” eight suggest a “Hold,” and one suggests a “Strong Sell.” Based on the average target price of $82.17, the stock has an upside potential of 15.6% from current levels. Its Street-high estimate of $97 further implies NEE stock can go as high as 36.5% in the next 12 months.It pays a dividend yield of 3.1%, compared to the utilities sector average of 3.7%. NextEra has a strong track reco ...

In this article, we will take a look at some of the best dividend stocks with consistent payouts.Investors have been rushing into high-dividend stocks, attracted by the promise of strong payouts as interest-rate cuts are anticipated later this year.According to Purpose Investments Inc., the five largest dividend-focused exchange-traded funds saw inflows of $17.5 billion by mid-July, almost ten times higher than at the beginning of 2024. However, the challenge for income seekers is that fewer US companies ar ...

Authored by Lawrence Wilson via The Epoch Times (emphasis ours),President Donald Trump has directed the Food and Drug Administration (FDA) to ramp up its efforts to ensure that advertising of prescription drugs directed to consumers is transparent and accurate.President Donald Trump speaks to the media while signing executive orders in the Oval Office of the White House on Sept. 5, 2025. Kevin Dietsch/Getty ImagesThat includes requiring drug makers to provide more information on the risks of using the drug, ...

The U.S. stock market experienced a mixed but generally resilient midday trading session on Friday, September 12, 2025, as investors continued to digest recent economic data and eagerly anticipate the Federal Reserve's upcoming interest rate decision. While major indexes showed varied performance, the overarching sentiment remains cautiously optimistic, largely fueled by expectations of a rate cut next week. The S&P 500 (SPX) and Nasdaq Composite (IXIC) held near record levels, while the Dow Jones Industria ...

智通财经APP获悉，艾伯维公司(AbbVie，ABBV.US)于周四宣布，已与所有涉诉仿制药企业达成和解， 解决了针对"仿制药企业计划推出Rinvoq仿制药"的相关诉讼。Rinvoq是艾伯维免疫治疗产品线中的核心 药物。 这家总部位于美国伊利诺伊州北芝加哥的制药巨头，已将Rinvoq及其"姊妹药"Skyrizi定位为重磅关节炎 药物修美乐(Humira)的潜在替代产品。修美乐于2023年失去了美国市场的独占权(即专利保护到期，仿 制药可合法进入)。 2025年上半年，Rinvoq的净销售额达到27亿美元，同比增长约53%;与之形成对比的是，同期修美乐在 美国市场的销售额同比下滑约63%。 此前，这些仿制药企业已向美国食品药品监督管理局(FDA)提交了"简化新药申请"(Abbreviated New Drug Application，ANDA)，寻求推出这款关节炎治疗药物的非专利版本(即仿制药)。 艾伯维在一份监管文件中表示，得益于此次达成的和解协议与授权协议，预计在2037年4月之前，针对 Rinvoq片剂的仿制药不会进入美国市场。 ...

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord... ...

The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation. ...

BREAKING: Core CPI Steady, Jobless Claims Highest Since Oct. 2021 AbbVie (ABBV) stock definitively broke out Thursday after the pharma titan announced it had entered a settlement deal that will stave off generic Rinvoq until April 2037. But Rinvoq and Skyrizi revenue also stepped up markedly. Though they work differently from Humira, the duo treat a number of the same conditions. Last year, Rinvoq brought in $5.97 billion in sales, accounting for almost 11% of total sales. Skyrizi generated $11.72 billion. ...